NCT05758389View on ClinicalTrials.gov

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

August 7, 2025

Study Completion Date

December 7, 2025

Conditions
Head and Neck Tumors
Interventions
DRUG

Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU

evaluate the efficacy and safety of immunotherapy combined with chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Department of Oncology, Drum Tower Hospital, Nanjing University School of Medicine, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER